# A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)

> **NCT02407756** · PHASE2 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 78 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Dupilumab

## Key facts

- **NCT ID:** NCT02407756
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-31
- **Primary completion:** 2016-03-31
- **Final completion:** 2016-03-31
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2020-11-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02407756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02407756, "A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02407756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*